A great deal is riding on the outcome of the Phase IIb study of Kezar Life Sciences, Inc.’s zetomipzomib (KZR-616) in lupus nephritis, and the company is throwing the few resources it has at completing the study. It is canning 41% of its workforce and has halted all drug discovery activities in an attempt to extend its cash runway to the study’s expected reporting date of 2026.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?